About OneSource
OneSource is a company based in Bengaluru (India) founded in 2023 was acquired by 360 One in November 2024. It operates as a Professional Services. OneSource has raised $155.46 million across 7 funding rounds from investors including 360 One, Tenshi Life Sciences and GMS Holdings. The company has 1,770 employees as of March 31, 2024. OneSource offers products and services including Sterile Injectables, Soft Gelatin Capsules, Drug-Device Combinations, and Complex Biologics. OneSource operates in a competitive market with competitors including Suanfarma, Enzene Biosciences, Hybio Pharmaceutical, Nephron Pharmaceuticals and Kardigan, among others.
- Headquarter Bengaluru, India
- Employees 1770 as on 31 Mar, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Onesource Specialty Pharma Limited
-
Annual Revenue
$169.14 M (USD)740.43as on Mar 31, 2025
-
Net Profit
-$2.1 M (USD)95.41as on Mar 31, 2025
-
EBITDA
$54.43 M (USD)0as on Mar 31, 2025
-
Total Equity Funding
$155.46 M (USD)
in 7 rounds
-
Latest Funding Round
$80 M (USD), Series C
Mar 19, 2021
-
Investors
360 One
& 13 more
-
Employee Count
1770
as on Mar 31, 2024
-
Acquired by
360 One
(Nov 21, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of OneSource
OneSource is a publicly listed company on the NSE with ticker symbol ONESOURCE in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of OneSource
OneSource offers a comprehensive portfolio of products and services, including Sterile Injectables, Soft Gelatin Capsules, Drug-Device Combinations, and Complex Biologics.
Sterile injectables are developed in complex dosage forms.
High-quality soft gelatin capsules are produced efficiently yearly.
Drug-device combinations are manufactured with flexible assembly stations.
Integrated solutions for biologics are offered with expertise.
People of OneSource
Unlock access to complete
Funding Insights of OneSource
OneSource has successfully raised a total of $155.46M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $80 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Series C — $80.0M
-
First Round
First Round
(22 Dec 2007)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2021 | Amount | Series C - OneSource | Valuation | TPG | |
| Nov, 2018 | Amount | Series B - OneSource | Valuation | Tenshi Life Sciences | |
| Feb, 2016 | Amount | Series B - OneSource | Valuation | GMS Holdings |
Investors in OneSource
OneSource has secured backing from 14 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include 360 One, Tenshi Life Sciences and GMS Holdings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Accel is recognized as a leading venture capital firm.
|
Founded Year | Domain | Location | |
|
Fund of funds focused on pre-seed and seed-stage companies
|
Founded Year | Domain | Location |
Investments & Acquisitions by OneSource
Financial Statements - OneSource
Onesource Comparisons
Competitors of OneSource
OneSource operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Suanfarma, Enzene Biosciences, Hybio Pharmaceutical, Nephron Pharmaceuticals and Kardigan, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Generics, nutraceuticals, and APIs are developed by Suanfarma.
|
|
| domain | founded_year | HQ Location |
Company specializing in development of Biosimilars
|
|
| domain | founded_year | HQ Location |
Polypeptide drugs and APIs are developed and manufactured.
|
|
| domain | founded_year | HQ Location |
Sterile pharmaceutical products are manufactured and contract services are provided.
|
|
| domain | founded_year | HQ Location |
Biotech company developing personalized medicines for cardiovascular diseases
|
|
| domain | founded_year | HQ Location |
APIs and finished dosage forms are developed and manufactured.
|
Frequently Asked Questions about OneSource
OneSource was founded in 2023.
OneSource is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Neeraj Sharma is the current CEO of OneSource.
OneSource is a funded company, having raised a total of $155.46M across 7 funding rounds to date. The company's 1st funding round was a Series B of $31.15M, raised on Dec 22, 2007.
As of Mar 31, 2024, the latest employee count at OneSource is 1,770.
Annual revenue of OneSource is $169.14M as on Mar 31, 2025.
OneSource is established as a multimodal specialty pharmaceutical CDMO with comprehensive end-to-end capabilities across various technology platforms and therapeutic modalities. Services are provided in drug development, manufacturing, and delivery, covering sterile injectables, soft gelatin capsules, drug-device combinations, and complex biologics. Expertise is offered in process development, quality compliance, and tech transfer, ensuring market-ready solutions. Operations are supported by state-of-the-art facilities and a dedicated team of over 100 scientists and leaders, catering to diverse market demands in the healthcare sector.
OneSource's top competitors include Nephron Pharmaceuticals, Suanfarma and Enzene Biosciences.
OneSource offers Sterile Injectables, Soft Gelatin Capsules, Drug-Device Combinations, and Complex Biologics.
Yes, OneSource is publicly traded on NSE under the ticker symbol ONESOURCE.
OneSource has 14 investors. Key investors include 360 One, Tenshi Life Sciences, GMS Holdings, Menaka Gubbi, and B K Iyer.
The ticker symbol of OneSource is ONESOURCE on NSE.